More than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, and that was linked to higher mortality as well as higher Medicare costs.
More than 80% of metastatic breast cancer (MBC) is human epidermal growth factor receptor 2 (HER2)-negative, and has worse outcomes than HER2-positive MBC.
Despite that, more than one-quarter of elderly women with HER2-negative metastatic breast cancer did not receive care in accordance with National Comprehensive Cancer Network (NCCN) treatment guidelines, according to a recent study presented at Virtual ISPOR 2020. And care that is not in line with guidelines was linked to higher mortality as well as higher Medicare costs, according to the report.
Older patients are usually excluded from randomized controlled trials, noted study author Ami M. Vyas, PhD, MBA, of the University of Rhode Island, in her presentation. In addition, there is very limited evidence about the extent of the effect of care in line with guidelines among patience in this group.
The aim of this study was to examine the effect of guideline-concordant treatment among elderly women with HER2-negative MBC on all-cause mortality, breast cancer-specific mortality, and Medicare costs.
They performed a retrospective cohort study using the Surveillance, Epidemiology, End Results-Medicare (SEER) database, including women aged 66 years and older diagnosed with HER2-negative MBC during 2010-2013.
The aim of the study was to evaluate how guideline-concordant treatment impacted all-cause and breast cancer-specific mortality using adjusted Cox proportional hazards models. They also conducted a generalized linear model with log link and gamma distribution to examine the impact of guideline-concordant treatment on average monthly Medicare costs. The models were adjusted for patient demographic and socioeconomic characteristics, clinical and tumor characteristics, healthcare access, and external healthcare environmental factors.
Endocrine therapies and infused or oral therapies were pulled from the database. The analysis included a total of 1089 women. Of those, 72.3% received guideline-concordant initial treatment.
An unadjusted analysis showed that those who received guideline-concordant treatment survived longer than those who did not receive guideline-concordant treatment.
In adjusted analyses, women who did not receive guideline-concordant treatment had significantly higher hazards of all-cause mortality (hazard ratio [HR] = 2.143, P <.001) and deaths specific to breast cancer (HR = 1.989, P <.001) than those who received guideline-concordant treatment.
Average monthly Medicare costs among women who received guideline-concordant treatment were significantly lower than those who did not receive guideline-concordant care ($3036 vs. $6172, P <.0001) in the adjusted analysis.
The results show that clinical and economic outcomes can improve with care that aligns with guidelines.
Reference
Vyas A, Mantaian T, Kogut SJ. Guideline-concordant treatment and its impact on survival and costs among elderly women with HER2-negative metastatic breast cancer. Presented at: ISPOR 2020; May 18-20, 2020; Abstract TP1.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More